PLSE
PULSE BIOSCIENCES, INC.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$57.06
+9.31%Oct 22, 2026, 20:05 UTC
PULSE BIOSCIENCES, INC. announced it will report third-quarter 2026 business updates and financial results after market close on November 5, 2026, and hold a conference call at 1:30 p.m. PT / 4:30 p.m. ET.
Source:Oct 14, 2026, 11:00 UTC
Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center covering use of its nPulse Vybrance Percutaneous Electrode System and a clinical collaboration.
Source:Sep 15, 2026, 20:47 UTC
Pulse Biosciences terminated its at-the-market offering program under its prior equity distribution agreement with TD Securities (USA) LLC dated February 19, 2026.
Sep 15, 2026, 20:47 UTC
Pulse Biosciences entered into an equity distribution agreement with Mizuho Securities USA LLC as sales agent for an at-the-market offering of up to $85 million of common stock.
Aug 7, 2026, 00:13 UTC
Pulse Biosciences, Inc reported a second-quarter loss of $0.36 per share, missing the Zacks Consensus Estimate of a $0.31 loss and wider than the year-ago loss of $0.28 per share.